Merck & Co.'s Keytruda Is "Off to The Races"

Since launching in late 2014 sales of Merck amp Co s NYSE MRK Keytruda a cancer fighting drug are already growing quickly However a new FDA approval of Keytruda as a first line therapy for metastatic non small cell lung cancer could make Keytruda s sales pace accelerate